Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cancer cells

N. Zaffaroni, R. Silvestrini, L. Orlandi, A. Bearzatto, D. Gornati, R. Villa

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

The effect of taxol (TX) and cisplatin (CDDP), singly or in association, was assessed on two human ovarian cancer cell lines, one sensitive (A2780) and one resistant (A2780 cp8) to CDDP. Cell lines showed a similar sensitivity to TX, whereas different cytotoxicity results were obtained in the two cell lines as a function of TX and CDDP sequence. Specifically TX followed by CDDP induced simply additive effects in both cell lines, whereas the opposite sequence produced antagonistic effects in A2780 cells and synergistic effects in A2780 cp8 cells. TX, with or without CDDP, induced oligonucleosomal DNA fragmentation typical of the apoptotic process, but the biochemical mechanisms undergoing apoptosis were different in the two cell lines. In fact, in A2780 cells, TX (with or without CDDP) treatment markedly increased p53 as well as p21(waft) protein expression. In A2780 cp8 cells, drug treatment enhanced p53 levels, whereas the expression of p21(waft) was always undetectable at mRNA and protein levels. In the latter cell line, a premature activation of p34(cdc2) kinase was observed in correspondence with the drug-induced increase in the S-phase cell fraction. Such an activation was not ascribable to an increase in the overall expression of p34(cdc2) or cyclin B1 proteins, but to a dephosphorylation of p34(cdc2) kinase. Overall, our results indicate that TX-induced apoptosis in human ovarian cancer cells may be sustained by different events at the cell cycle-control level.

Original languageEnglish
Pages (from-to)1378-1385
Number of pages8
JournalBritish Journal of Cancer
Volume77
Issue number9
Publication statusPublished - 1998

Fingerprint

Cell Cycle Proteins
Paclitaxel
Ovarian Neoplasms
Cisplatin
Apoptosis
Cell Line
Biochemical Phenomena
Phosphotransferases
Cyclin B1
Proteins
DNA Fragmentation
Cell Cycle Checkpoints
S Phase
Pharmaceutical Preparations
Messenger RNA

Keywords

  • Apoptosis
  • Cell cycle-related proteins
  • Cisplatin
  • Ovarian cancer
  • Taxol

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cancer cells. / Zaffaroni, N.; Silvestrini, R.; Orlandi, L.; Bearzatto, A.; Gornati, D.; Villa, R.

In: British Journal of Cancer, Vol. 77, No. 9, 1998, p. 1378-1385.

Research output: Contribution to journalArticle

@article{1864d16372124c90b036b99d9288985f,
title = "Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cancer cells",
abstract = "The effect of taxol (TX) and cisplatin (CDDP), singly or in association, was assessed on two human ovarian cancer cell lines, one sensitive (A2780) and one resistant (A2780 cp8) to CDDP. Cell lines showed a similar sensitivity to TX, whereas different cytotoxicity results were obtained in the two cell lines as a function of TX and CDDP sequence. Specifically TX followed by CDDP induced simply additive effects in both cell lines, whereas the opposite sequence produced antagonistic effects in A2780 cells and synergistic effects in A2780 cp8 cells. TX, with or without CDDP, induced oligonucleosomal DNA fragmentation typical of the apoptotic process, but the biochemical mechanisms undergoing apoptosis were different in the two cell lines. In fact, in A2780 cells, TX (with or without CDDP) treatment markedly increased p53 as well as p21(waft) protein expression. In A2780 cp8 cells, drug treatment enhanced p53 levels, whereas the expression of p21(waft) was always undetectable at mRNA and protein levels. In the latter cell line, a premature activation of p34(cdc2) kinase was observed in correspondence with the drug-induced increase in the S-phase cell fraction. Such an activation was not ascribable to an increase in the overall expression of p34(cdc2) or cyclin B1 proteins, but to a dephosphorylation of p34(cdc2) kinase. Overall, our results indicate that TX-induced apoptosis in human ovarian cancer cells may be sustained by different events at the cell cycle-control level.",
keywords = "Apoptosis, Cell cycle-related proteins, Cisplatin, Ovarian cancer, Taxol",
author = "N. Zaffaroni and R. Silvestrini and L. Orlandi and A. Bearzatto and D. Gornati and R. Villa",
year = "1998",
language = "English",
volume = "77",
pages = "1378--1385",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cancer cells

AU - Zaffaroni, N.

AU - Silvestrini, R.

AU - Orlandi, L.

AU - Bearzatto, A.

AU - Gornati, D.

AU - Villa, R.

PY - 1998

Y1 - 1998

N2 - The effect of taxol (TX) and cisplatin (CDDP), singly or in association, was assessed on two human ovarian cancer cell lines, one sensitive (A2780) and one resistant (A2780 cp8) to CDDP. Cell lines showed a similar sensitivity to TX, whereas different cytotoxicity results were obtained in the two cell lines as a function of TX and CDDP sequence. Specifically TX followed by CDDP induced simply additive effects in both cell lines, whereas the opposite sequence produced antagonistic effects in A2780 cells and synergistic effects in A2780 cp8 cells. TX, with or without CDDP, induced oligonucleosomal DNA fragmentation typical of the apoptotic process, but the biochemical mechanisms undergoing apoptosis were different in the two cell lines. In fact, in A2780 cells, TX (with or without CDDP) treatment markedly increased p53 as well as p21(waft) protein expression. In A2780 cp8 cells, drug treatment enhanced p53 levels, whereas the expression of p21(waft) was always undetectable at mRNA and protein levels. In the latter cell line, a premature activation of p34(cdc2) kinase was observed in correspondence with the drug-induced increase in the S-phase cell fraction. Such an activation was not ascribable to an increase in the overall expression of p34(cdc2) or cyclin B1 proteins, but to a dephosphorylation of p34(cdc2) kinase. Overall, our results indicate that TX-induced apoptosis in human ovarian cancer cells may be sustained by different events at the cell cycle-control level.

AB - The effect of taxol (TX) and cisplatin (CDDP), singly or in association, was assessed on two human ovarian cancer cell lines, one sensitive (A2780) and one resistant (A2780 cp8) to CDDP. Cell lines showed a similar sensitivity to TX, whereas different cytotoxicity results were obtained in the two cell lines as a function of TX and CDDP sequence. Specifically TX followed by CDDP induced simply additive effects in both cell lines, whereas the opposite sequence produced antagonistic effects in A2780 cells and synergistic effects in A2780 cp8 cells. TX, with or without CDDP, induced oligonucleosomal DNA fragmentation typical of the apoptotic process, but the biochemical mechanisms undergoing apoptosis were different in the two cell lines. In fact, in A2780 cells, TX (with or without CDDP) treatment markedly increased p53 as well as p21(waft) protein expression. In A2780 cp8 cells, drug treatment enhanced p53 levels, whereas the expression of p21(waft) was always undetectable at mRNA and protein levels. In the latter cell line, a premature activation of p34(cdc2) kinase was observed in correspondence with the drug-induced increase in the S-phase cell fraction. Such an activation was not ascribable to an increase in the overall expression of p34(cdc2) or cyclin B1 proteins, but to a dephosphorylation of p34(cdc2) kinase. Overall, our results indicate that TX-induced apoptosis in human ovarian cancer cells may be sustained by different events at the cell cycle-control level.

KW - Apoptosis

KW - Cell cycle-related proteins

KW - Cisplatin

KW - Ovarian cancer

KW - Taxol

UR - http://www.scopus.com/inward/record.url?scp=0031920710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031920710&partnerID=8YFLogxK

M3 - Article

C2 - 9652752

AN - SCOPUS:0031920710

VL - 77

SP - 1378

EP - 1385

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 9

ER -